AMPITRIN

Usual adult dosage Ear, nose and throat infections: 250 mg four times a day Bronchitis: Routine therapy: 250 mg four times daily High dose therapy: 1 g four times daily Pneumonia: 500 mg four times daily Urinary tract infections: 500 mg three times daily Gastro-intestinal infections: 500 - 750 mg three to four times daily Enteric fevers: Acute: 1-2 g four times daily for two weeks Carriers: 1-2 g four times daily for four to 12 weeks Gonorrhoea: 2 g orally with 1 g probenecid as a single dose.

Repeated doses are recommended for the treatment of females.

Usual dosage for the elderly:

As for adults; reduced doses may be required in those with impaired renal function.

Usual children’s dosage (under 10 years):

Half adult routine dosage. All recommended dosages are a guide only. In severe infections the above dosages may be increased at the direction of the physician. Ampicillin should be given a half to one hour before meals. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Consult local or national prescribing guidelines for antibiotic use before prescribing. Where possible, use only where antibiotic sensitivity is known or suspected. e, creatinine clearance <10 mL/min) reduction in dose or extension of the dose interval should be considered.

In patients undergoing dialysis, an additional dose should be administered after dialysis. Method of administration For oral administration only

Hypersensitivity reactions:

If any hypersensitivity reaction occurs, the treatment should be discontinued. Skin rash, pruritis and urticaria have been reported occasionally. The incidence is higher in patients suffering from infectious mononucleosisand acute or chronic leukaemia of lymphoid origin.

Purpura has also been reported. Rarely, skin reactions such as erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. 4) has been reported rarely.

Renal effects:

Interstitial nephritis can occur rarely.

Gastrointestinal reactions:

Effects include nausea, vomiting and diarrhoea. Pseudomembraneous colitis and haemorrhagic colitis has been reported rarely.

Hepatic effects:

As with other beta-lactam antibiotics, hepatitis and cholestatic jaundice have been reported rarely. As with most other antibiotics, a moderate and transient increase in transaminases has been reported.

Haematological effects:

As with other beta-lactams, haematological effects including transient leucopenia, transient thrombocytopenia and haemolytic anaemia have been reported rarely. Prolongation of bleeding time and prothrombin time have also been reported rarely.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

g. Candida or Pseudomonas. Anaphylactic (anaphylactoid) reactions Before initiating therapy with ampicillin, careful enquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics. Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients receiving beta-lactam antibiotics.

Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of beta-lactam hypersensitivity. 2). Use in patients with infections Ampicillin should be avoided if infectious mononucleosis and/or acute and chronic lymphatic leukaemia are suspected as erythematous rashes are more common with these conditions following administration of ampicillin.

1.